During the past decade, Vitreo-Retinal Associates, PC conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 12 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 10 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vitreo-Retinal Associates, PC" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Jaeb Center for Health Research" with 5 trials sponsored, "Kodiak Sciences Inc" with 4 trials sponsored, "Allergan" with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vitreo-Retinal Associates, PC" #1 collaborator was "National Eye Institute (NEI)" with 5 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "National Institutes of Health (NIH)" with 3 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "MEDARVA Foundation" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Vitreo-Retinal Associates, PC" are "Diabetic Macular Edema" (7 trials), "Geographic Atrophy" (3 trials), "Macular Degeneration" (2 trials), "Age-Related Maculopathy" (1 trials) and "Choroidal Neovascularization" (1 trials). Many other conditions were trialed in "Vitreo-Retinal Associates, PC" in a lesser frequency.

Most popular intervention types in "Vitreo-Retinal Associates, PC" are "Drug" (18 trials), "Other" (9 trials), "Device" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (8 trials), "Aflibercept" (5 trials), "KSI-301" (4 trials), "Ranibizumab" (4 trials) and "Faricimab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Vitreo-Retinal Associates, PC" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Vitreo-Retinal Associates, PC". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Vitreo-Retinal Associates, PC, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Vitreo-Retinal Associates, PC, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".